In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
Funding innovation under pressure: examining the role of commercial health insurance in Europe
Europe’s health systems are facing growing pressure amidst strained public budgets, ageing populations, and increasing treatment costs, prompting urgent questio